A randomized Phase I vaginal safety study of three concentrations of C31G vs. Extra Strength Gynol II
- 1 September 2004
- journal article
- clinical trial
- Published by Elsevier in Contraception
- Vol. 70 (3) , 233-240
- https://doi.org/10.1016/j.contraception.2004.04.010
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Safety of single daily use for one week of C31G HEC gel in womenContraception, 2002
- Microbicides—evaluating multiple formulations of C31GContraception, 2002
- Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trialThe Lancet, 2002
- Inactivation of human immunodeficiency virus type 1 by nonoxynol-9, C31G, or an alkyl sulfate, sodium dodecyl sulfateAntiviral Research, 1999
- Variations in vaginal epithelial surface appearance determined by colposcopic inspection in healthy, sexually active womenHuman Reproduction, 1999
- The microbicidal agent C31G inhibits Chlamydia trachomatis infectivity in vitroAntimicrobial Agents and Chemotherapy, 1997
- Assessment of the anti-microbial agent C31G as a spermicide: Comparison with nonoxynol-9Contraception, 1996
- Evaluation of a Surfactant Mixture C31G as a Teat Dip by a Modified Excised Teat ModelJournal of Dairy Science, 1984